Drug intelligence / Profile preview

KDF1901-R0

Development stage: Unknown
Lead developer: Kyungdong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**KDF1901-R0** is an oral fixed-dose antihypertensive combination developed by Kyungdong Pharmaceutical containing **valsartan 80 mg and amlodipine 5 mg**. It combines angiotensin II type 1 receptor blockade by valsartan with L-type calcium-channel inhibition by amlodipine to reduce vasoconstriction and lower blood pressure. KDF1901-R0 was used as the 4-week run-in dual-therapy regimen in a Phase 3 study of the related triple combination KDF1901 for essential hypertension. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07116863))

Brand names: Valodipine
Other names: valsartan/amlodipineamlodipine/valsartan

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on KDF1901-R0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KDF1901-R0.

Explore the full profile